Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 1, 2012, Pages 89-103

  Maneiro, Jose Ramon ^a   Salgado, Eva ^a   Gomez Reino, Juan J ^a,b   Carmona, Loreto ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

Effectiveness; Efficacy; Safety; Sarcoidosis; TNF antagonist

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL BLEEDING; ACUTE RESPIRATORY FAILURE; ARTICLE; CLINICAL FEATURE; COCHRANE LIBRARY; CONJUNCTIVAL HEMORRHAGE; DESCRIPTIVE RESEARCH; DISEASE REGISTRY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBASE; EVIDENCE BASED MEDICINE; EYE DISEASE; GASTROINTESTINAL INFECTION; GLAUCOMA; HERPES ZOSTER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; KERATITIS; LUNG INFECTION; LUNG SARCOIDOSIS; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RETINA DETACHMENT; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SPAIN; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SARCOIDOSIS; SPAIN; TIME-TO-TREATMENT; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84864086248     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.12.006     Document Type: Article

References (85)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999, 160(2):736-755.
2. Paramothayan S., Lasserson T., Walters E.H. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003, (3). CD003536.
3. Kiltz U., Braun J. Use of methotrexate in patients with sarcoidosis. Clin Exp Rheumatol 2010, 28(5 Suppl 61):S183-S185.
4. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115(1):1-20.
5. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168(9):4620-4627.
6. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(10):601-611.
7. Baughman R.P., Strohofer S.A., Buchsbaum J., Lower E.E. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990, 115(1):36-42.
8. Ziegenhagen M.W., Benner U.K., Zissel G., Zabel P., Schlaak M., Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997, 156(5):1586-1592.
9. Baughman R.P., Lower E.E. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990, 142(6 Pt. 1):1268-1271.
10. Tong Z., Dai H., Chen B., Abdoh Z., Guzman J., Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest 2003, 124(4):1526-1532.
11. Tavares J.L., Wangoo A., Dilworth P., Marshall B., Kotecha S., Shaw R.J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997, 91(1):31-39.
12. Carmona L., Gomez-Reino J.J. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8(3):R72.
13. Curtis J.R., Jain A., Askling J., Bridges S.L., Carmona L., Dixon W., et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010, 40(1):2-14. e1.
14. Carmona L. Actualización de BIOBADASER. Reumatol Clin 2009, 5(Suppl 1):66-70.
15. Descalzo M.A., Carmona L. Biobadaser 2.0: análisis y tendencias en 2009. Reumatol Clin 2010, 6:240-243. Grupo de estudio BIOBADASER.
16. Sackett D.L., Rosenberg W.M., Gray J.A., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312(7023):71-72.
17. Baughman R.P., Bradley D.A., Raymond L.O., Lower E.E., Kerr M.A., Winget D.B., et al. Double blind randomized trial of a tumor necrosis factor receptor antagonist (Etanercept) for treatment of chronic ocular sarcoidosis. Am J Respir Crit Care Med [serial on the Internet] 2002, (Suppl 8). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/275/CN-00382275/frame.html.
18. Baughman R.P., Bradley D.A., Lower E.E. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005, 43(1):7-11.
19. Baughman R.P., Judson M.A., Drent M., Costabel U., du Bois R., Kavuru M., et al. Impact of withdrawal of infliximab after 6 months treatment [Abstract]. Proceedings of the American Thoracic Society [serial on the Internet] 2006, http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/785/CN-00591785/frame.html.
20. Judson M.A., Baughman R.P., Kavuru M., Costabel U., Drent M., DuBois R., et al. Improvement in 6 minute walk distance in a double-blind randomized placebo-controlled trial of infliximab for chronic pulmonary sarcoidosis [Abstract]. Proceedings of the American Thoracic Society [serial on the Internet] 2006, http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/517/CN-00591517/frame.html.
21. Rossman M.D., Newman L.S., Baughman R.P., Teirstein A., Weinberger S.E., Keenan G.F., et al. A double-blind randomized placebo-controlled trial of infliximab in active pulmonary sarcoidosis [Abstract] 2005, http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/642/CN-00525642/frame.html.
22. Summaries for patients. A new anti-inflammatory therapy (Infliximab) for complicated sarcoidosis. Ann Intern Med 2001, 135(1):S20.
23. Wells A.U. Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive. Eur Respir J 2008, 31(6):1148-1149.
24. Cook M.C. Infliximab therapy for complicated sarcoidosis. Ann Intern Med 2002, 137(4):296-297. author reply 297.
25. Corbett J. Treating CNS sarcoidosis with infliximab and mycophenolate mofetil [Short Survey]. Curr Neurol Neurosci Rep 2009, 9(5):339-340.
26. Kahler C.M., Heininger P., Loeffler-Ragg J., Vogelsinger H. Infliximab therapy in pulmonary sarcoidosis. Am J Respir Crit Care Med 2007, 176(4):417. author reply 418.
27. Morcos Z. Refractory neurosarcoidosis responding to infliximab. Neurology 2003, 60(7):1220-1221. author reply 1221.
28. O'Connor T.M., Shanahan F., Bredin C.P. Infliximab therapy for complicated sarcoidosis. Ann Intern Med 2002, 137(4):296-297. author reply 297.
29. Chintamaneni S., Patel A.M., Pegram S.B., Patel H., Roppelt H. Dramatic response to infliximab in refractory neurosarcoidosis. Ann Indian Acad Neurol 2010, 13(3):207-210.
30. Cufi-Benet M., Sabadell C., Codina O. [Adalimumab in the treatment of parotid sarcoidosis]. Arch Bronconeumol 2010, 46(1):49-50.
31. Dhingra N., Morgan J., Dick A.D. Switching biologic agents for uveitis. Eye (Lond) 2009, 23(9):1868-1870.
32. Elfferich M.D., Nelemans P.J., Ponds R.W., De Vries J., Wijnen P.A., Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010, 80(3):212-219.
33. Jonker G., van Kan G., Hoor-de Groot E.T., Drent M. Improvement of the clinical response to infiximab in refractory sarcoidosis by reducing the dose interval [Abstract]. European Respiratory Journal [serial on the Internet] 2007, (Suppl 51). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/679/CN-00642679/frame.html.
34. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89(5):533-536.
35. Malaviya A.N., Sawhney S., Kapoor S., Garg S. Vertebral sarcoid mimicking ankylosing spondylitis or just a co-incidence?. J Assoc Physicians India 2010, 58:709-711.
36. Marnane M., Lynch T., Scott J., Stack J., Kelly P.J. Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab. J Neurol 2009, 256(1):139-140.
37. Menon Y., Cucurull E., Reisin E., Espinoza L.R. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004, 328(3):173-175.
38. Migliore A., Signore A., Capuano A., Bizzi E., Massafra U., Vacca E., et al. Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. Eur Rev Med Pharmacol Sci 2008, 12(2):127-130.
39. Saurenmann R.K., Levin A.V., Rose J.B., Parker S., Rabinovitch T., Tyrrell P.N., et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006, 45(8):982-989.
40. Simonini G., Taddio A., Cattalini M., Caputo R., De Libero C., Naviglio S., et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011, 63(4):612-618.
41. Thielen A.M., Barde C., Saurat J.H., Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology 2009, 219(1):59-62.
42. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18(1):70-74.
43. Hoitsma E., Faber C.G., van Santen-Hoeufft M., De Vries J., Reulen J.P., Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23(1):73-77.
44. Petropoulos I.K., Vaudaux J.D., Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008, 225(5):457-461.
45. Tuchinda C., Wong H.K. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol 2006, 5(6):538-540.
46. Sorrentino D., Avellini C., Zearo E. Colonic sarcoidosis, infliximab, and tuberculosis: a cautionary tale. Inflamm Bowel Dis 2004, 10(4):438-440.
47. Stagaki E., Mountford W.K., Lackland D.T., Judson M.A. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest 2009, 135(2):468-476.
48. Baughman R.P., Shipley R., Desai S., Drent M., Judson M.A., Costabel U., et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009, 136(2):526-535.
49. Drent M., Costabel U., Shipley R., Desai S., Judson M., du Bois R., et al. Changes of chest roentgenogram during a double blind randomized trial of infliximab for chronic pulmonary sarcoidosis [Abstract]. European Respiratory Journal [serial on the Internet] 2006, (Suppl 50). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/578/CN-00623578/frame.html.
50. Loza M.J., Brodmerkel C., Du Bois R.M., Judson M.A., Costabel U., Drent M., et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol 2011, 18(6):931-939.
51. Sweiss N.J., Barnathan E.S., Lo K., Judson M.A., Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27(1):49-56.
52. Evrard P., Evrard A.S., Gouzou M., Brisbois D., Quatresooz P., Engelen M. Cardiac sarcoidosis: a case report. Rev Med Liege 2008, 63(12):707-709.
53. Gallagher M., Quinones K., Cervantes-Castaneda R.A., Yilmaz T., Foster C.S. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91(10):1341-1344.
54. Mana J., Capdevila O., Solanich X., Jucgla A., Marcoval J. [Lupus pernio. A report of a series of 8 patients]. Rev Clin Esp 2010, 210(11):550-555.
55. Markert J.M., Powell K., Tubbs R.S., Riley K.O., Hadley M.N., Palmer C.A. Necrotizing neurosarcoid: three cases with varying presentations. Clin Neuropathol 2007, 26(2):59-67.
56. Baughman R.P. Clinical characteristics of patients participating in multicenter randomized double-blind placebo-controlled trial evaluating the safety and efficacy of infliximab in patients with chronic sarcoidosis with pulmonary involvement [Abstract] 2005, http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/441/CN-00524441/frame.html.
57. Suzuki J., Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept therapy. Jpn J Ophthalmol 2009, 53(4):439-440.
58. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174(7):795-802.
59. Judson M.A., Baughman R.P., Costabel U., Flavin S., Lo K.H., Kavuru M.S., et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology [serial on the Internet] 2008, (6). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/728/CN-00637728/frame.html.
60. Baughman R., Lo L., Guzzo C., Barnathan E. Efficacy of infliximab in improving lupus pernio in patients receiving treatment for chronic pulmonary sarcoidosis. Journal of the American Academy of Dermatology [serial on the Internet] 2006, (Suppl 3). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/504/CN-00623504/frame.html.
61. Baughman R.P., Lower E.E., Bradley D.A., Raymond L.A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest [serial on the Internet] 2005, (2). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/879/CN-00523879/frame.html.
62. Rossman M.D., Newman L.S., Baughman R.P., Teirstein A., Weinberger S.E., Miller W., et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases: official journal of WASOG/World Association of Sarcoidosis and Other Granulomatous Disorders [serial on the Internet] 2006, (3). http://www.mrw.interscience.wiley.com/cochrane/clcentral/articles/292/CN-00621292/frame.html.
63. Aguiar M., Marcal N., Mendes A.C., Bugalho de Almeida A. Infliximab for treating sarcoidosis patients. Portuguese experience. Rev Port Pneumol 2011, 17(2):85-93.
64. Crouser E.D., Lozanski G., Fox C.C., Hauswirth D.W., Raveendran R., Julian M.W. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-α therapy. Chest 2010, 137(6):1432-1435.
65. Doty J.D., Mazur J.E., Judson M.A. Treatment of sarcoidosis with infliximab. Chest 2005, 127(3):1064-1071.
66. Hostettler K.E., Studler U., Tamm M., Brutsche M.H. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012, (83):218-224.
67. Jounieaux F., Chapelon C., Valeyre D., Israel Biet D., Cottin V., Tazi A., et al. [Infliximab treatment for chronic sarcoidosis-a case series]. Rev Mal Respir 2010, 27(7):685-692.
68. Keijsers R.G., Verzijlbergen J.F., van Diepen D.M., van den Bosch J.M., Grutters J.C. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25(2):143-149.
69. Moravan M., Segal B.M. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009, 72(4):337-340.
70. Panselinas E., Rodgers J.K., Judson M.A. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009, 14(4):522-528.
71. Pritchard C., Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004, 63(3):318-320.
72. Saleh S., Ghodsian S., Yakimova V., Henderson J., Sharma O.P. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006, 100(11):2053-2059.
73. Santos E., Shaunak S., Renowden S., Scolding N.J. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010, 81(3):241-246.
74. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124(1):177-185.
75. Tournadre A., Ledoux-Eberst J., Poujol D., Dubost J.J., Ristori J.M., Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: Two cases. Joint Bone Spine 2008, 75(2):215-218.
76. D'Haens G., Swijsen C., Noman M., Lemmens L., Ceuppens J., Agbahiwe H., et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001, 96(9):2564-2568.
77. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121(5):1088-1094.
78. N Engl J Med 2005, 352(4):351-361. Wegener's granulomatosis Etanercept trial (WGET) research group.
79. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117(2):244-279.
80. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301(2):418-426.
81. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001, 69(3):1847-1855.
82. Olleros M.L., Guler R., Corazza N., Vesin D., Eugster H.P., Marchal G., et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002, 168(7):3394-3401.
83. Carmona L., Descalzo M.A., Ruiz-Montesinos D., Manero-Ruiz F.J., Perez-Pampin E., Gomez-Reino J.J. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011, 50(1):85-92.
84. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66(7):880-885.
85. Kievit W., Fransen J., Adang E.M., den Broeder A.A., Bernelot Moens H.J., Visser H., et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011, 50(1):196-203.